Hledání v detailu akcií
Top akcie
NázevNávštěvy
31 086
5 608
5 407
5 167
4 025
3 252
2 615
2 509
2 369
1 694
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,24
KB-0,22
PKN97,6497,90,66
Msft0,61
Nokia4,724,7491,00
IBM0,13
Daimler AG57,7257,760,70
PFE0,71
22.9.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.9.2018
Heron Therapeutics (NASDAQ Cons)
Závěr k 21.9.2018 Změna (%) Změna (USD) Objem obchodů (ks)
31,40 -5,14 -1,70 2 607 603
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.9.2018
Popis společnosti
Obecné informace
Název společnostiHeron Therapeutics Inc
TickerHRTX
Kmenové akcie:Ordinary Shares
RICHRTX.O
ISINUS4277461020
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 1.2.2018 145
Akcie v oběhu k 24.7.2018 77 734 284
Počet akcionářů k 31.12.2017 124
MěnaUSD
Kontaktní informace
Ulice4242 Campus Point Ct Ste 200
MěstoSAN DIEGO
PSČ92121-1513
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 503 662 626

Business Summary: Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Financial Summary: BRIEF: For the six months ended 30 June 2018, Heron Therapeutics Inc revenues increased from $12.1M to $28.8M. Net loss decreased 2% to $90.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 7% to $4.6M (expense), Stock-based Compensation in SGA decrease of 6% to $4.8M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 22.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardKevin Tang5130.7.201230.7.2012
President, DirectorRobert Rosen621.5.20131.5.2013
Chief Executive Officer, DirectorBarry Quart6124.4.20171.5.2013
Chief Financial Officer, Senior Vice President - FinanceRobert Hoffman52
Executive Vice President - Drug DevelopmentKimberly Manhard5827.1.201627.1.2016
Senior Vice President, General Counsel, Business Development, Corporate SecretaryDavid Szekeres44
Senior Vice President - Pharmaceutical and Preclinical Research and DevelopmentThomas Ottoboni59
Vice President - Human ResourcesSean Ristine48